S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
3 tech outperformers adored by analysts
New CBOE “special perk” helps traders target income every weekend (Ad)
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
High short interest stocks: this popular trend is re-emerging
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
3 tech outperformers adored by analysts
New CBOE “special perk” helps traders target income every weekend (Ad)
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
High short interest stocks: this popular trend is re-emerging
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
3 tech outperformers adored by analysts
New CBOE “special perk” helps traders target income every weekend (Ad)
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
High short interest stocks: this popular trend is re-emerging
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Freshworks gets juiced on its AI customer engagement platform
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
New CBOE “special perk” helps traders target income every weekend (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
3 tech outperformers adored by analysts
New CBOE “special perk” helps traders target income every weekend (Ad)
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
High short interest stocks: this popular trend is re-emerging

NeoGenomics (NEO) Stock Price, News & Analysis

$18.34
+0.40 (+2.23%)
(As of 12/8/2023 08:57 PM ET)
Compare
Today's Range
$17.77
▼
$18.35
50-Day Range
$11.67
▼
$19.51
52-Week Range
$8.70
▼
$20.54
Volume
582,500 shs
Average Volume
967,824 shs
Market Capitalization
$2.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

NeoGenomics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
3.6% Upside
$19.00 Price Target
Short Interest
Bearish
4.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.60mentions of NeoGenomics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$49,083 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.36) to ($0.28) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.38 out of 5 stars

Medical Sector

893rd out of 942 stocks

Testing Laboratories Industry

1st out of 1 stocks

See Top Rated MarketRank™ Stocks Here

NEO stock logo

About NeoGenomics Stock (NASDAQ:NEO)

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

NEO Stock Price History

NEO Stock News Headlines

December 5, 2023 | finance.yahoo.com
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
November 14, 2023 | finance.yahoo.com
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
December 11, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
November 13, 2023 | finance.yahoo.com
Wall Street Analysts See a 28.17% Upside in NeoGenomics (NEO): Can the Stock Really Move This High?
November 8, 2023 | markets.businessinsider.com
NeoGenomics’ Strong Performance and Growth Potential: Reasons Behind Analyst’s Buy Rating and Increased Price Target
November 7, 2023 | finance.yahoo.com
NeoGenomics reports 3Q revenue up 18%, narrower net loss; boosts year forecast
November 7, 2023 | markets.businessinsider.com
What 6 Analyst Ratings Have To Say About NeoGenomics
November 7, 2023 | finance.yahoo.com
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2023 Earnings Call Transcript
December 11, 2023 | DTI Trader (Ad)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
November 6, 2023 | finance.yahoo.com
Compared to Estimates, NeoGenomics (NEO) Q3 Earnings: A Look at Key Metrics
November 6, 2023 | seekingalpha.com
NeoGenomics, Inc. 2023 Q3 - Results - Earnings Call Presentation
November 6, 2023 | msn.com
NeoGenomics Non-GAAP EPS of $0.00 beats by $0.08, revenue of $152M beats by $10M
November 6, 2023 | finance.yahoo.com
NeoGenomics Reports Third Quarter 2023 Results
November 6, 2023 | finance.yahoo.com
NeoGenomics Inc (NEO) Reports 18% Revenue Increase in Q3 2023
November 5, 2023 | markets.businessinsider.com
Here's what Wall Street expects from Neogenomics's earnings report
November 3, 2023 | morningstar.com
NeoGenomics Inc NEO
October 27, 2023 | finance.yahoo.com
Wall Street Analysts Think NeoGenomics (NEO) Could Surge 35.08%: Read This Before Placing a Bet
October 25, 2023 | msn.com
NeoGenomics: Short-Term Upsides Possible, Long-Term Not Supported By Economic Value
October 24, 2023 | nasdaq.com
Morgan Stanley Maintains Neogenomics (NEO) Equal-Weight Recommendation
October 24, 2023 | finance.yahoo.com
Bull of the Day: NeoGenomics (NEO)
October 24, 2023 | finance.yahoo.com
NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios
October 20, 2023 | msn.com
Goldman Sachs Maintains Neogenomics (NEO) Buy Recommendation
October 17, 2023 | msn.com
Piper Sandler Maintains Neogenomics (NEO) Overweight Recommendation
October 17, 2023 | finance.yahoo.com
NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023
October 16, 2023 | markets.businessinsider.com
Where NeoGenomics Stands With Analysts
October 13, 2023 | finance.yahoo.com
NeoGenomics (NEO) Upgraded to Strong Buy: What Does It Mean for the Stock?
October 5, 2023 | finance.yahoo.com
Investors in NeoGenomics (NASDAQ:NEO) have unfortunately lost 69% over the last three years
See More Headlines
Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Testing laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NEO
CUSIP
N/A
CIK
1077183
Web
www.neogenomics.com
Phone
(239) 768-0600
Fax
239-690-4237
Employees
2,100
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$19.00
High Stock Price Target
$25.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+3.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-144,250,000.00
Net Margins
-16.76%
Pretax Margin
-18.67%
Return on Equity
-4.95%
Return on Assets
-2.81%

Debt

Debt-to-Equity Ratio
0.57
Current Ratio
6.32
Quick Ratio
6.06

Sales & Book Value

Annual Sales
$509.73 million
Price / Sales
4.59
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.90 per share
Price / Book
2.32

Miscellaneous

Outstanding Shares
127,470,000
Free Float
125,809,000
Market Cap
$2.34 billion
Optionable
Optionable
Beta
1.32

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Christopher Michael Smith BSc (Age 60)
    CEO & Director
    Comp: $3.52M
  • Mr. Jeffrey S. Sherman M.B.A. (Age 57)
    Chief Financial Officer
    Comp: $492.31k
  • Mr. Vishal Sikri (Age 47)
    President of Advanced Diagnostics Division
    Comp: $1.21M
  • Mr. Warren Stone (Age 50)
    President of Clinical Division
    Comp: $722.79k
  • Ms. Cynthia J. Dieter (Age 48)
    Chief Accounting Officer
  • Mr. Greg Sparks
    Chief Technology Officer
  • Ms. Kendra Sweeney
    Vice President of Investor Relations & Communications
  • Ms. Alicia Olivo (Age 39)
    General Counsel & Corporate Secretary
  • Mr. Hutan Hashemi J.D. (Age 44)
    Chief Compliance Officer
  • Dr. Derek Lyle M.D.
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions














NEO Stock Analysis - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NEO shares.
View NEO analyst ratings or view top-rated stocks.

What is NeoGenomics' stock price target for 2024?

11 Wall Street analysts have issued twelve-month price targets for NeoGenomics' stock. Their NEO share price targets range from $17.00 to $25.00. On average, they expect the company's share price to reach $19.00 in the next year. This suggests a possible upside of 3.6% from the stock's current price.
View analysts price targets for NEO or view top-rated stocks among Wall Street analysts.

How have NEO shares performed in 2023?

NeoGenomics' stock was trading at $9.24 on January 1st, 2023. Since then, NEO shares have increased by 98.5% and is now trading at $18.34.
View the best growth stocks for 2023 here.

When is NeoGenomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our NEO earnings forecast.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings data on Monday, November, 6th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.05. The medical research company had revenue of $151.95 million for the quarter, compared to the consensus estimate of $142.15 million. NeoGenomics had a negative trailing twelve-month return on equity of 4.95% and a negative net margin of 16.76%.

What ETFs hold NeoGenomics' stock?

ETFs with the largest weight of NeoGenomics (NASDAQ:NEO) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and iShares U.S. Healthcare Providers ETF (IHF).SPDR S&P 600 Small Cap ETF (SLY).

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its FY 2023 earnings guidance on Monday, November, 6th. The company provided earnings per share (EPS) guidance of -$0.18--$0.15 for the period, compared to the consensus EPS estimate of -$0.28. The company issued revenue guidance of $585.00 million-$592.00 million, compared to the consensus revenue estimate of $573.19 million.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Brown Advisory Inc. (6.47%), Schroder Investment Management Group (1.97%), Emerald Advisers LLC (1.51%), Northern Trust Corp (1.24%), Emerald Mutual Fund Advisers Trust (1.22%) and Fred Alger Management LLC (1.04%). Insiders that own company stock include Alicia C Olivo, Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Lawrence Martin Weiss, Mark Mallon, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends.

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does NeoGenomics have any subsidiaries?
The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.
Read More
This page (NASDAQ:NEO) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -